ArticleCancer discovery2020
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Abstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 303 papers.
0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
303 citing papers in PubMed.
- Novel model of pyroptosis-related molecular signatures for prognosis prediction of clear cell renal cell carcinoma patients.International journal of medical sciences · 2024Trial
- Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance.Cancer research · 2026Article
- The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026Review
- PhSAN induces PANoptosis via targeting RNF25-mediated endoplasmic reticulum stress.Cell insight · 2026Article
- Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death.Apoptosis : an international journal on programmed cell death · 2026Article
- Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers.Cell death and differentiation · 2026Article
- TFAP2A links drug resistance to antitumor immunity.bioRxiv : the preprint server for biology · 2026Article
- Review
- GSDME acts as an epigenetic modifier to promote melanoma development via centriole biogenesis regulator PLK4.Cell death and differentiation · 2026Article
- Cell death pathways and targeting therapeutics in cancer therapy.Acta pharmacologica Sinica · 2026Review
- The pyroptosis and inflammatory response-related long noncoding RNA signature as a novel prognostic biomarker of head and neck squamous cell carcinoma.Discover oncology · 2026Article
- Targeting methionine-induced pyroptosis enhances anti-tumor immunity.Science China. Life sciences · 2026Article
- Statins targeting mevalonate-geranylgeranyl diphosphate pathway inhibit proliferation in NK/T lymphoma by promoting pyroptosis.Translational oncology · 2026Article
- The Crosstalk Mechanisms Between Ferroptosis and Pyroptosis and Their Applications in Diseases: From Molecular Networks to Clinical Strategies.Journal of cellular and molecular medicine · 2026Review
- Leveraging the crosstalk between cGAS-STING and pyroptosis by nanomedicine to enhance antitumor immunity.Journal of nanobiotechnology · 2026Review
- TOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy.Nature cell biology · 2026Article
- Single-Cell Transcriptomic Analysis of Chemotherapy-Induced Changes in Osteosarcoma With a Pyroptosis-Related Gene-Based Prognostic Model.Journal of cellular and molecular medicine · 2026Article
- Pyroptosis: Turning Up the Heat on Cancer.Annual review of immunology · 2026Review
- Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.Cancer immunology research · 2026Article
243 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Dan A Erkes *Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Weijia Cai *Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0003-1469-8991
Ileine M SanchezDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Timothy J PurwinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0002-7053-8039
Corey RogersDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Conroy O FieldDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Adam C BergerDepartment of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Edward J HartsoughDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ulrich RodeckSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Emad S AlnemriDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania. Andrew.Aplin@Jefferson.edu Emad.Alnemri@Jefferson.edu.
Andrew E AplinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania. Andrew.Aplin@Jefferson.edu Emad.Alnemri@Jefferson.edu.ORCID https://orcid.org/0000-0002-2734-3244
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MCysteine Proteases in ApoptosisR01AR055398 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI ALNEMRI, EMAD S · 2008 to 2018
$4.2MRequest for Supplemental Funds aligned to CA160495R01CA160495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2012 to 2022
$3.6MTargeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4MRegulation of the Cell Death Program by DFNA5R01AR074564 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI ALNEMRI, EMAD S · 2019 to 2023
$2.7MMutant BRAF-regulated transcription factors in melanoma progressionR01CA196278 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2015 to 2019
$1.8MThe role of CADM1 in malignant melanomaR00CA207855 · NCI · DREXEL UNIVERSITY · PI HARTSOUGH, EDWARD · 2018 to 2020
$701kThe role of CADM1 in malignant melanomaK99CA207855 · NCI · THOMAS JEFFERSON UNIVERSITY · PI HARTSOUGH, EDWARD · 2017 to 2018
$219kNCI NIH HHS K99 CA207855NCI NIH HHS P30 CA056036NCI NIH HHS R00 CA207855NCI NIH HHS R01 CA160495NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA196278NIAMS NIH HHS R01 AR055398NIAMS NIH HHS R01 AR074564
Abstract
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDendritic CellsDisease Models, AnimalDrug Resistance, NeoplasmFemaleHumansImmune Checkpoint InhibitorsMaleMelanomaMiceMitogen-Activated Protein Kinase KinasesMutationProof of Concept StudyProtein Kinase InhibitorsBRAF protein, humanImmune Checkpoint InhibitorsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.